U.S. Markets open in 3 hrs 33 mins
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,776.50
    -1.70 (-0.10%)
     
  • Silver

    22.53
    -0.04 (-0.17%)
     
  • EUR/USD

    1.1734
    +0.0004 (+0.0352%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    23.09
    -2.62 (-10.19%)
     
  • GBP/USD

    1.3635
    -0.0029 (-0.2100%)
     
  • USD/JPY

    109.5200
    +0.3000 (+0.2747%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,056.17
    -7.67 (-0.72%)
     
  • FTSE 100

    7,057.59
    +76.61 (+1.10%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Exelixis' Cabozantinib Shows Overall Objective Response Rates of 38% In Genitourinary Tumor Settings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Exelixis Inc (NASDAQ: EXELannounces final data from Phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including seven expansion cohorts, evaluating cabozantinib in combination with either Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) or nivolumab plus ipilimumab in patients with refractory metastatic genitourinary tumors.

  • Exelixis presented the data at the American Society of Clinical Oncology's Genitourinary Cancers Symposium.

  • In the study, cabozantinib, in combination with either nivolumab alone (n=64) or nivolumab plus ipilimumab (n=56), demonstrated an objective response rate (ORR) of 38%, with an 11.1% complete response (CR) rate.

  • In 33 previously treated metastatic urothelial carcinoma patients, ORR was 42.4%, and the CR rate was 21%. The ORR in 16 previously treated metastatic renal cell carcinoma patients was 62.5%. The ORR was 20% for patients with urachal adenocarcinoma, 85.7% for squamous cell carcinoma of the bladder, and 44.4% for penile carcinoma.

  • The median overall survival for the entire population was 15.9 months. Median progression-free survival was 5.5 months, and the median duration of response was 22.8 months.

  • Recommended Phase 2 doses determined for the combination of cabozantinib plus nivolumab were cabozantinib 40 mg daily and 3 mg/kg of nivolumab every two weeks. The recommended phase 2 doses determined for the combination of cabozantinib plus nivolumab and ipilimumab were cabozantinib 40 mg daily, 3 mg/kg of nivolumab every two weeks, and 1 mg/kg ipilimumab every three weeks.

  • Price Action: EXEL gained 1.41% at $22.22 in premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.